Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Country/Region as subject
Language
Affiliation country
Publication year range
1.
Trop Med Int Health ; 26(4): 421-427, 2021 04.
Article in English | MEDLINE | ID: mdl-33406316

ABSTRACT

OBJECTIVES: In this retrospective study, we evaluated the diagnostic accuracy of molecular tests (MT) for the detection of DR-TB, compared to the gold standard liquid-based drug susceptibility testing (DST) in Karakalpakstan. METHODS: A total of 6670 specimens received in the Republican TB No 1 Hospital Laboratory of Karakalpakstan between January and July 2017 from new and retreatment patients were analysed. Samples were tested using Xpert MTB/RIF and line probe assays (LPA) for the detection of mutations associated with resistance. The sensitivity and specificity of MTs were calculated relative to results based on DST. RESULTS: The accuracy of MT for detection of rifampicin resistance was high, with sensitivity and specificity over 98%. However, we observed reduced sensitivity of LPA for detection of resistance; 86% for isoniazid (95% CI 82-90%), 86% for fluoroquinolones (95% CI 68-96%), 70% for capreomycin (95% CI 46-88%) and 23% for kanamycin (95% CI 13-35%). CONCLUSIONS: We show that MTs are a useful tool for rapid and safe diagnosis of DR-TB; however, clinicians should be aware of their limitations. Although detection of rifampicin resistance was highly accurate, our data suggest that resistance mutations circulating in the Republic of Karakalpakstan for other drugs were not detected by the methods used here. This merits further investigation.


Subject(s)
Antibiotics, Antitubercular/therapeutic use , Drug Resistance, Bacterial , Microbial Sensitivity Tests/methods , Mycobacterium tuberculosis/growth & development , Tuberculosis/drug therapy , Capreomycin/therapeutic use , Fluoroquinolones/therapeutic use , Humans , Isoniazid/therapeutic use , Kanamycin/therapeutic use , Mutation , Mycobacterium tuberculosis/genetics , Polymerase Chain Reaction , Reproducibility of Results , Retrospective Studies , Rifampin/therapeutic use , Tuberculosis/microbiology , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Multidrug-Resistant/microbiology , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/microbiology , Uzbekistan
SELECTION OF CITATIONS
SEARCH DETAIL